AZTA stock icon

Azenta
AZTA

$57.77
8.1%

Market Cap: 3.11B

 

About: Azenta Inc is a provider of life sciences solutions, enabling impactful breakthroughs and therapies to market faster. It provides a full suite of reliable cold-chain sample management solutions and genomic services across areas such as drug development, clinical research and advanced cell therapies for the industry's top pharmaceutical, biotech, academic and healthcare institutions globally. The company has two reportable segments that are Life Sciences Products and Life Sciences Services. It generates a substantial part of its revenue from its Life Sciences Services segment.

Employees: 3,400

0
Funds holding %
of 6,702 funds
0
Analysts bullish %
of 11 analysts
News positive %

Fund manager confidence

Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)

15% more first-time investments, than exits

New positions opened: 45 | Existing positions closed: 39

2% more funds holding

Funds holding: 311 [Q4 2023] → 317 (+6) [Q1 2024]

0% more funds holding in top 10

Funds holding in top 10: 2 [Q4 2023] → 2 (+0) [Q1 2024]

7.18% less ownership

Funds ownership: 104.75% [Q4 2023] → 97.57% (-7.18%) [Q1 2024]

14% less capital invested

Capital invested by funds: $3.8B [Q4 2023] → $3.28B (-$524M) [Q1 2024]

17% less repeat investments, than reductions

Existing positions increased: 101 | Existing positions reduced: 122

38% less call options, than puts

Call options by funds: $8.19M | Put options by funds: $13.2M

Research analyst outlook

11 Wall Street Analysts provided 1 year price forecasts over the past 6 months

Low target
$53
8%
downside
Avg. target
$70
21%
upside
High target
$79
37%
upside

11 analyst ratings

positive
64%
neutral
36%
negative
0%
Evercore ISI Group
Vijay Kumar
8%downside
$53
In-Line
Maintained
2 Jul 2024
Needham
David Saxon
19%upside
$69
Buy
Maintained
9 May 2024
Needham
David Saxon
30%upside
$75
Buy
Maintained
8 Apr 2024
Evercore ISI Group
Vijay Kumar
4%upside
$60
In-Line
Maintained
4 Apr 2024
Jefferies
Matthew Stanton
11%upside
$64
Hold
Initiated
4 Apr 2024

Financial journalist opinion